Skye Bioscience Free Cash Flow (FCF) History (SKYE)
Skye Bioscience reported −$43.1M in free cash flow for fiscal 2025, a decrease of $16.2M from the previous fiscal year.
View full Skye Bioscience company overviewSkye Bioscience free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$43.1M | −$16.2M | — | — |
| 2024 | 2024-12-31 | −$26.8M | −$12.9M | — | — |
| 2023 | 2023-12-31 | −$14.0M | −$1.2M | — | — |
| 2022 | 2022-12-31 | −$12.8M | −$6.2M | — | — |
| 2021 | 2021-12-31 | −$6.6M | −$504,393 | — | — |
| 2020 | 2020-12-31 | −$6.1M | −$2.1M | — | — |
| 2018 | 2018-12-31 | −$3.9M | −$596,460 | — | — |
| 2017 | 2017-12-31 | −$3.4M | $213,119 | — | — |
| 2016 | 2016-12-31 | −$3.6M | $165,913 | — | — |
| 2015 | 2015-12-31 | −$3.7M | −$2.0M | — | — |
| 2014 | 2014-12-31 | −$1.8M | −$1.7M | — | — |
| 2013 | 2013-10-31 | −$63,611 | — | — | — |
Skye Bioscience quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.1M | $3.6M | — | — |
| Q1 2026 | 2026-03-31 | −$8.6M | $633,875 | — | — |
| Q4 2025 | 2025-12-31 | −$9.8M | −$1.5M | — | — |
| Q3 2025 | 2025-09-30 | −$13.4M | −$6.6M | — | — |
| Q2 2025 | 2025-06-30 | −$10.7M | −$3.6M | — | — |
| Q1 2025 | 2025-03-31 | −$9.2M | −$4.5M | — | — |
| Q4 2024 | 2024-12-31 | −$8.2M | −$4.4M | — | — |
| Q3 2024 | 2024-09-30 | −$6.8M | −$2.7M | — | — |
| Q2 2024 | 2024-06-30 | −$7.1M | −$5.1M | — | — |
| Q1 2024 | 2024-03-31 | −$4.7M | −$648,521 | — | — |
| Q4 2023 | 2023-12-31 | −$3.9M | $1.0M | — | — |
| Q3 2023 | 2023-09-30 | −$4.1M | −$2.0M | — | — |
| Q2 2023 | 2023-06-30 | −$2.0M | $912,461 | — | — |
| Q1 2023 | 2023-03-31 | −$4.1M | −$1.1M | — | — |
| Q4 2022 | 2022-12-31 | −$4.9M | −$2.9M | — | — |
| Q3 2022 | 2022-09-30 | −$2.1M | −$553,734 | — | — |
| Q2 2022 | 2022-06-30 | −$2.9M | −$1.2M | — | — |
| Q1 2022 | 2022-03-31 | −$2.9M | −$1.6M | — | — |
| Q4 2021 | 2021-12-31 | −$2.0M | −$229,731 | — | — |
| Q3 2021 | 2021-09-30 | −$1.5M | $460,844 | — | — |
| Q2 2021 | 2021-06-30 | −$1.7M | −$643,887 | — | — |
| Q1 2021 | 2021-03-31 | −$1.4M | −$92,671 | — | — |
| Q4 2020 | 2020-12-31 | −$1.8M | −$779,006 | — | — |
| Q3 2020 | 2020-09-30 | −$2.0M | −$1.2M | — | — |
| Q2 2020 | 2020-06-30 | −$1.0M | $34,699 | — | — |
| Q1 2020 | 2020-03-31 | −$1.3M | −$211,892 | — | — |
| Q4 2018 | 2018-12-31 | −$1.0M | −$351,378 | — | — |
| Q3 2018 | 2018-09-30 | −$816,282 | −$304,554 | — | — |
| Q2 2018 | 2018-06-30 | −$1.1M | $167,225 | — | — |
| Q1 2018 | 2018-03-31 | −$1.1M | $105,366 | — | — |
| Q4 2016 | 2016-12-31 | −$662,779 | −$654,023 | — | — |
| Q3 2016 | 2016-09-30 | −$511,728 | −$519,939 | — | — |
| Q2 2016 | 2016-06-30 | −$1.2M | −$1.2M | — | — |
| Q1 2016 | 2016-03-31 | −$1.2M | −$1.1M | — | — |
| Q4 2013 | 2013-10-31 | −$8,756 | — | — | — |
| Q3 2013 | 2013-07-31 | $8,211 | — | — | — |
| Q2 2013 | 2013-04-30 | −$3,106 | — | — | — |
| Q1 2013 | 2013-01-31 | −$59,960 | — | — | — |
Skye Bioscience free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$6.1M to −$43.1M, a net decrease of $37.0M. Skye Bioscience's latest reported quarter, Q2 2026, generated −$7.1M in free cash flow, an increase of $3.6M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Skye Bioscience filings at SEC.gov ↗